<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00314886</url>
  </required_header>
  <id_info>
    <org_study_id>CHU63-0009</org_study_id>
    <nct_id>NCT00314886</nct_id>
  </id_info>
  <brief_title>Effect of Butyrogenic Fibers in IBS Patients</brief_title>
  <official_title>Effect of an Enriched Butyrogenic Fibres Diet on Rectal Sensitivity in Healthy Control and IBS Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Recherche Agronomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EA 3848 UdA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ERT-CIDAM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Despite there being no clearcut advantages, one of the most common recommendations in IBS
      management is to increase the amount of dietary fibres. In some IBS patients fibres have a
      deleterious effect on pain and bloating. It has been shown that butyrate can increase colonic
      sensitivity in rats. Our purpose is to study whether butyrogenic fibres can modify rectal
      sensitivity and symptoms in IBS and healthy control through a modification of colonic flora.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite there being no clearcut advantages, one of the most common recommendations in IBS
      management is to increase the amount of dietary fibres. In some IBS patients fibres have a
      deleterious effect on pain and bloating. It has been shown that butyrate can increase colonic
      sensitivity in rats. Our purpose is to study whether butyrogenic fibres can modify rectal
      sensitivity and symptoms in IBS and healthy control through a modification of colonic flora.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2005</start_date>
  <completion_date type="Anticipated">July 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Discomfort threshold to rectal distension</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rectal sensitivity : first sensation and threshold for first sensation of the need to defecate.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal discomfort (questionnaire)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (questionnaire)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Taxonomic composition of colonic flora</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional composition of colonic flora</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fermentation profile of ingested fibre</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diet</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female aged 18-60 years

          -  Normal volunteers and patients with IBS assessed by Rome II criteria

          -  Effective contraception

          -  Affiliated to National Health Service

          -  Having received oral and written information about the study

          -  Having provided her written informed consent

        Exclusion Criteria:

          -  Significant clinical or biological abnormality

          -  Organic gastrointestinal disease

          -  Subjects having lower than 15g/day or higher than 20g/day fibres intake

          -  Antibiotic treatment during the month preceding the pre inclusion day

          -  Antispasmodics, antidiarrheics, laxatives, and prokinetics during the week preceding
             the pre inclusion day and during all the study period.

          -  Digestive surgery tract except appendectomy and cholecystectomy

          -  Alcohol abuse

          -  Drug addiction

          -  Major psychiatric disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Dapoigny, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel Dapoigny, Pr</last_name>
    <phone>(33) 04 73 75 05 23</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Dapoigny, Pr</last_name>
      <phone>(33) 04 73 75 05 23</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Dunlop SP, Spiller RC. Nutritional issues in irritable bowel syndrome. Curr Opin Clin Nutr Metab Care. 2001 Nov;4(6):537-40. Review.</citation>
    <PMID>11706290</PMID>
  </reference>
  <reference>
    <citation>Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet. 1994 Jul 2;344(8914):39-40.</citation>
    <PMID>7912305</PMID>
  </reference>
  <reference>
    <citation>Harmsen HJ, Raangs GC, He T, Degener JE, Welling GW. Extensive set of 16S rRNA-based probes for detection of bacteria in human feces. Appl Environ Microbiol. 2002 Jun;68(6):2982-90.</citation>
    <PMID>12039758</PMID>
  </reference>
  <reference>
    <citation>Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ. 1992 Jan 11;304(6819):87-90.</citation>
    <PMID>1737146</PMID>
  </reference>
  <reference>
    <citation>Jones VA, McLaughlan P, Shorthouse M, Workman E, Hunter JO. Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. Lancet. 1982 Nov 20;2(8308):1115-7.</citation>
    <PMID>6128447</PMID>
  </reference>
  <reference>
    <citation>King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet. 1998 Oct 10;352(9135):1187-9.</citation>
    <PMID>9777836</PMID>
  </reference>
  <reference>
    <citation>Snook J, Shepherd HA. Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1994 Oct;8(5):511-4.</citation>
    <PMID>7865643</PMID>
  </reference>
  <reference>
    <citation>Tarrerias AL, Millecamps M, Alloui A, Beaughard C, Kemeny JL, Bourdu S, Bommelaer G, Eschalier A, Dapoigny M, Ardid D. Short-chain fatty acid enemas fail to decrease colonic hypersensitivity and inflammation in TNBS-induced colonic inflammation in rats. Pain. 2002 Nov;100(1-2):91-7.</citation>
    <PMID>12435462</PMID>
  </reference>
  <reference>
    <citation>Bourdu S, Dapoigny M, Chapuy E, Artigue F, Vasson MP, Dechelotte P, Bommelaer G, Eschalier A, Ardid D. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology. 2005 Jun;128(7):1996-2008.</citation>
    <PMID>15940632</PMID>
  </reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2006</study_first_submitted>
  <study_first_submitted_qc>April 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2006</study_first_posted>
  <last_update_submitted>January 18, 2011</last_update_submitted>
  <last_update_submitted_qc>January 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Pr Michel Dapoigny</name_title>
    <organization>CHU Clermont-Ferrand</organization>
  </responsible_party>
  <keyword>Diet</keyword>
  <keyword>Fiber</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Colonic Flora</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

